Editas Medicine Announces Second Quarter 2026 Results and Business Updates on August 10, 2026 Benefit cash runway Collaboration EDIT-401 program EPS exophthalmos producing substance Gene Modification Impaired in vivo Myers Squibb collaboration restructuring Revenue second-quarter +
CSL Takes $5B Impairment Charge and Revenue Cut on May 12, 2026 argenx Vyvgart Biological Factors CSL-Behring decline expansion Hizentra Immunoglobulins Impaired Kankakee Illinois Limited (extensiveness) plasma-derived therapies Privigen revenue guidance cut SMPX gene +
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights on November 12, 2025 capitalization clinical-stage biopharma development aspects exophthalmos producing substance financial results Impaired Market net loss Nkarta Operating expenses Q3 research +
Curtain Closes on Takeda's Cell Therapy Efforts on October 02, 2025 Biological Factors Cell Therapy Gamma/Delta T-Lymphocyte Impaired research discontinuation strategic shift Takeda +
Sanofi's E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge on February 13, 2025 charge amounts Clinical Trials Escherichia coli Failure (biologic function) Impaired Johnson & Johnson Phase 3 sanofi Vaccines +
AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset on February 10, 2025 Alexion AstraZeneca charge amounts Complement Inactivating Agents drug discontinuation Drug Industry Impaired Vemircopan +